BLUE BELL, Pa., March 5, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE AMEX: INO) announced today that its SynCon® therapeutic vaccine for human papillomavirus (HPV) types 6 and 11, which are associated with head & neck cancers and genital warts, among other conditions, induced strong antigen-specific CD8+ T cells in mice. This vaccine is complementary to Inovio's VGX-3100, a therapeutic vaccine targeting cervical dysplasias and cancers caused by HPV types 16 and 18, which is in a phase II clinical study for CIN 2/3. This positive animal data mirrors the similarly robust T-cell responses induced by VGX-3100 in earlier mice studies. These results were reported in a peer-reviewed paper titled, "Induction of robust cellular immunity against HPV6 and HPV11 in mice by DNA vaccine encoding for E6/E7 antigen," which has been published in Human Vaccines & Immunotherapeutics.
Inovio Therapeutic Vaccine For Head & Neck And Other HPV-Related Cancers Induces Robust T-Cell Immune Response In Mice
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.